Isis Pharmaceuticals, Inc.
) recently announced encouraging results from a phase I study on
its candidate, ISIS-CRP. In the study, ISIS-CRP demonstrated
significant reduction of the endotoxin-induced CRP response
without impacting other key immune modulators including
TNF-alpha, IL-6, and other cytokines and chemokines in healthy
The company stated in its press release that selective
reduction of CRP could offer a safer approach for treating
patients suffering from chronic inflammatory diseases, such as
Isis Pharma is evaluating the use of ISIS-CRP in RA patients with
chronically elevated CRP levels. Data from the phase II study is
expected in mid-2013.
Isis Pharma is also evaluating the safety and efficacy of the
candidate in patients suffering from paroxysmal atrial
fibrillation (AF) in another phase II study. Data is expected in
the first half of 2014.
Last month, Isis Pharma received a $7.5 million milestone payment
). The payment primarily relates to the initiation of a phase
II/III clinical study of ISIS-TTRRx. The study will span 15
months enrolling 200 patients. Isis is developing ISIS-TTRRx in
collaboration with Glaxo for the potential treatment of
transthyretin (TTR) amyloidosis.
We note that Isis Pharma's lead product, Kynamro (mipomersen
sodium), received FDA approval in Jan 2013 for the treatment of
familial hypercholesterolemia (FH). Isis Pharma's partner
) is marketing the product in the US. Sanofi is also looking to
get the drug approved in the rest of the world including Europe.
Isis Pharma currently carries a Zacks Rank #3 (Hold).
) looks more attractive in the pharma sector with a Zacks Rank #1
CYTOKINETCS INC (CYTK): Free Stock Analysis
GLAXOSMITHKLINE (GSK): Free Stock Analysis
ISIS PHARMACEUT (ISIS): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.